Cargando…
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
The lethality of patients with ovarian cancer (OC) remains high. Current treatment strategies often do not lead to the desired outcome due to the development of therapy resistance, resulting in high relapse rates. Additionally, clinical trials testing immunotherapy against OC have failed to reach si...
Autores principales: | Berckmans, Yani, Hoffert, Yannick, Vankerckhoven, Ann, Dreesen, Erwin, Coosemans, An |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385967/ https://www.ncbi.nlm.nih.gov/pubmed/37513979 http://dx.doi.org/10.3390/pharmaceutics15071792 |
Ejemplares similares
-
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
por: Baert, Thaïs, et al.
Publicado: (2019) -
Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy
por: Berckmans, Yani, et al.
Publicado: (2023) -
Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer
por: De Bruyn, Christine, et al.
Publicado: (2021) -
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer
por: Sprooten, Jenny, et al.
Publicado: (2021) -
Intraperitoneal alpha therapy with (224)Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model
por: Wouters, Roxanne, et al.
Publicado: (2022)